CClinicalTrials.gg
CompletedNCT05479747Updated Mar 1, 2024Results posted

Efficacy of Trypsin-Chymotrypsin On Post-operative Pain After Single Visit Root Canal Treatment

A Phase 4 interventional study of post operative analgesics in Effect of Drug, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2021, registered Jul 2022).
Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Achieving effective pain control after endodontic treatment is still a disruptive event to all the clinicians. There is a knowledge gap regarding the effect of protease on postoperative pain following root canal treatment, therefore, the efficacy of Trypsin-Chymotrypsin on post endodontic pain was evaluated clinically in a randomized triple-blind trial.

Read the detailed description

This study approved by the institutional review of board (IRB) of the ethics committee at the Faculty of Dentistry, Ain Shams University, Cairo, Egypt under approval number FDASU-Rec IM012110.

This study design was a prospective, parallel triple blind phase IV randomized clinical trial.

A pilot study was performed on five patients in each group and its results were used for sample size calculation. Based upon the results of the pilot study; the minimum estimated sample size was a total of 52 patients. Sample size was increased to 60 for compensation of the drop-out. Sample size calculation was performed by using G*Power Version 3.1.9.2.

All included patient signed an informed consent prior to start of the study.

Randomization and blinding:60 patients who had the eligibility criteria were allocated randomly according to the ratio of 1:1 to each group. Randomization was performed by using computer software (www.randome.org).

Allocation concealment mechanism: Random sequence generations, allocation concealment and interventions preparation were occurred before starting by the help of one independent person who concealed the allocation sequence from the investigators in opaque and tightly sealed envelope. Before study implementation, this person also divided the medicaments into 60 tightly sealed opaque envelopes contained a treatment with the recommended dose and labeled by one-digit alphabetical symbol (X, Y, Z, R).

Implementation of the study: After root canal treatment, post-operative medicaments were assigned by telephone verification. This independent person informed the operator which drug should be prescribed in the form of X, Y, Z or R to maintain operator blinding. The investigators used the computerized generated randomization protocol for each eligible patient. So, patients were enrolled into each of the groups and prescribed with different post-operative intervention. All pain assessment forms and data were monitored by a trained clinician. He was not a part of the study team.The statistician was also blinded.

Patient history revealed diffuse lingering pulpal pain. Cold sensibility testing with Endo-Ice (1,1,1,2 Tetrafluoroethane; Hygenic Corp) indicated a moderate to severe response. Vitality was matched with the contra lateral as control. The vitality was established clinically by blood observation in the canal. Teeth had no sensitivity to percussion or palpation. Radiographically had normal periapical condition. Endodontic treatment procedures were done by the same operator in the post-graduate clinic of the Endodontic Department of the Faculty of Dentistry, Ain Shams University, Egypt. Patients were assessed by a trained clinician who was not a part of the study team.

85 patients were assessed for the eligibility criteria. 25 individuals were excluded due to different reasons. 60 participants were included. They were randomized into four groups (N = 15).

Group I: (ibuprofen) Participants were given ibuprofen 600 mg 3 times per day for 3 days after each of the three meals.

Group II: (Trypsin-Chymotrypsin) Participants were given (Trypsin 5 mg Chymotrypsin 5 mg3 times per day for 3 days one hour before each of the three meals.

Group III: (ibuprofen + Trypsin Chymotrypsin) Participants were given ibuprofen 600 mg 3 times per day for 3 days after each of the three meals and (Trypsin 5 mg Chymotrypsin 5 mg) 3 times per day for 3 days one hour before each of the three meals.

Group IV: (placebo) Participants were given postoperatively placebo sugar pills 3 times per day for 3 day.

All participant were asked to record their postoperative pain intensity at 6h ,12h ,24h, 48h ,72h following obturation. They also asked to report the occurrence of any side effects.

Data analysis:

Statistical analysis was undertaken with IBM SPSS Statistics. Age difference was analyzed by using one-way ANOVA test. For Pain records, Kruskal-Wallis test for comparison among the four groups, Friedman's test for changes by time intervals in each group and for pair-wise comparisons when Kruskal-Wallis or Friedman's test was significant, Dunn's test was used. Chi-square test was used for qualitative data. The significance level was set at P ≤ 0.05.

02

Conditions studied

  • Effect of Drug

Keywords

  • Trypsin and chymotrypsin
  • Ibuprofen
  • postoperative pain
  • Analgesic drugs
  • pain control drugs
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Egyptian healthy symptomatic both gender patients
  • aged (18- 40) years old
  • with no physical disability, facial paresthesia or psychological problems
  • had mandibular first molars with symptomatic irreversible pulpitis and with normal appearance radiographically.

Exclusion criteria

Exclusion criteria:

  • The vulnerable group
  • participants who un abled to read and fill the questionnaire,
  • those who took preoperative analgesics 24 h prior to treatment
  • those with known sensitivity to the drugs used in this study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Ibuprofen (Brufen)

    Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.

    Drug: post operative analgesics

  • Experimental
    Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)

    Participants were handed Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.

    Drug: post operative analgesics

  • Active comparator
    Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)

    Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals and Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.

    Drug: post operative analgesics

  • Placebo comparator
    Placebo pills (Sugar pills)

    Participants were handed postoperatively sugar pills (Placebo pills) (Department of pharmaceutics \& industrial pharmacy at Faculty of pharmacy Ain Shams University, Cairo, Egypt) 3 times daily for 3 days in tightly sealed envelope with an included written paper contained the instruction for dose administration.

    Drug: post operative analgesics

Interventions

  • Drugpost operative analgesics

    post-operative pain killer

    Also known as: pain control drug

06

What researchers measure

Primary outcomes

  1. Effect of Trypsin-Chymotrypsin on Post-operative Pain After Single Endodontic Treatment in Teeth With Symptomatic Irreversible Pulpitis

    analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.

    Time frame: from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)

Secondary outcomes

  1. Synergistic Effect With NSAIDS

    analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.

    Time frame: from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)

  2. Reported Side Effect

    assessed by Passive surveillance of harm. It depends on adverse effects reported by the participants.

    Time frame: from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)

07

Results

Posted Mar 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneIbuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)
Started15151515
Completed15151515
Not completed0000

Outcome measures

PrimaryEffect of Trypsin-Chymotrypsin on Post-operative Pain After Single Endodontic Treatment in Teeth With Symptomatic Irreversible Pulpitis

analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.

Time frame:
from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)
Reported as:
Mean · score on a scale
Effect of Trypsin-Chymotrypsin on Post-operative Pain After Single Endodontic Treatment in Teeth With Symptomatic Irreversible Pulpitis
score on a scaleIbuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)
after 6 hours follow up3.47 ± 1.553.53 ± 1.462.93 ± 1.336.13 ± 0.64
after 12 hours follow up2 ± 1.411.87 ± 1.511.4 ± 0.914.47 ± 0.64
after 24 hours follow up0.87 ± 1.060.8 ± 1.080.2 ± 0.413.4 ± 0.74
after 48 hours follow up0 ± 00.13 ± 0.520 ± 02.47 ± 0.64
after 72 hours follow up0 ± 00.13 ± 0.520 ± 01.2 ± 0.77
SecondarySynergistic Effect With NSAIDS

analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.

Time frame:
from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)
Reported as:
Mean · score on a scale
Synergistic Effect With NSAIDS
score on a scaleIbuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)
after 6 hours follow up3.47 ± 1.553.53 ± 1.462.93 ± 1.336.13 ± 0.64
after 12 hours follow up2 ± 1.411.87 ± 1.511.4 ± 0.914.47 ± 0.64
after 24 hours follow up0.87 ± 1.060.8 ± 1.080.2 ± 0.413.4 ± 0.74
after 48 hours follow up0 ± 00.13 ± 0.520 ± 02.47 ± 0.64
after 72 hours follow up0 ± 00.13 ± 0.520 ± 01.2 ± 0.77
SecondaryReported Side Effect

assessed by Passive surveillance of harm. It depends on adverse effects reported by the participants.

Time frame:
from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)
Reported as:
Mean · reported side effects
Reported Side Effect
reported side effectsIbuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)
after 6 hours0 ± 00 ± 00 ± 00 ± 0
after 12 hours0 ± 00 ± 00 ± 00 ± 0
after 24 hours0 ± 00 ± 00 ± 00 ± 0
after 48 hours0 ± 00 ± 00 ± 00 ± 0
after 72 hours0 ± 00 ± 00 ± 00 ± 0

Adverse events

Collected over from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen (Brufen)0/15 (0%)0/15 (0%)0/15 (0%)
Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)0/15 (0%)0/15 (0%)0/15 (0%)
Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)0/15 (0%)0/15 (0%)0/15 (0%)
Placebo Pills (Sugar Pills)0/15 (0%)0/15 (0%)0/15 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)Total
Mean27.5 ± 827.8 ± 827.9 ± 8.128 ± 7.727.8 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Ibuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)Total
Female879832
Male786728
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ibuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)Total
Egyptian1515151560
Region of Enrollment
Region of Enrollment(participants)Ibuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)Total
Egypt1515151560
pre-operative pain scores
pre-operative pain scores(units on a scale)Ibuprofen (Brufen)Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)Placebo Pills (Sugar Pills)Total
Mean8.4 ± 0.638.53 ± 1.138.13 ± 1.368.73 ± 0.88.4 ± 0.98
08

Study locations

1 site
  • Ahmed Abdel Rahman Hashem
    Cairo, Egypt
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Sep 9, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05479747
Lead sponsor
Ain Shams University
Responsible party
Alaa Adly Abd El-Sattar Mahmoud (principal investigator, Ain Shams University) — Principal investigator
First posted
Jul 29, 2022
Start date
Jun 1, 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Results posted
Mar 1, 2024
Last update
Mar 1, 2024

Study contacts

Ahmed A Hashem, PHD
study chair · Head of endodontic department Faculty of dentistry Ain Shams University, cairo,Egypt
Tariq Y Abdel Rahman, PHD
study director · Lecturer, Endodontic Department, Faculty of Dentistry, Ain Shams University
Alaa A Abd El Sattar, Master
principal investigator · Faculty of Dentistry, Ain Shams University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion